MAB Stock Overview
A biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mabion S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł17.26 |
| 52 Week High | zł23.60 |
| 52 Week Low | zł15.50 |
| Beta | 0.98 |
| 1 Month Change | -6.09% |
| 3 Month Change | 3.60% |
| 1 Year Change | -0.69% |
| 3 Year Change | -77.29% |
| 5 Year Change | -76.58% |
| Change since IPO | 28.04% |
Recent News & Updates
Recent updates
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24
Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth
Nov 28Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts
Jun 02Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?
Jul 09Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News
Jun 04Is Mabion (WSE:MAB) Using Too Much Debt?
Dec 22Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate
Sep 11How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?
Feb 24Shareholder Returns
| MAB | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -2.8% | 1.5% | -1.2% |
| 1Y | -0.7% | -17.3% | 15.2% |
Return vs Industry: MAB exceeded the Polish Biotechs industry which returned -17.3% over the past year.
Return vs Market: MAB underperformed the Polish Market which returned 15.2% over the past year.
Price Volatility
| MAB volatility | |
|---|---|
| MAB Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: MAB has not had significant price volatility in the past 3 months.
Volatility Over Time: MAB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 244 | Krzysztof Kaczmarczyk | www.mabion.eu |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2.
Mabion S.A. Fundamentals Summary
| MAB fundamental statistics | |
|---|---|
| Market cap | zł278.96m |
| Earnings (TTM) | zł42.34m |
| Revenue (TTM) | zł146.11m |
6.6x
P/E Ratio1.9x
P/S RatioIs MAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAB income statement (TTM) | |
|---|---|
| Revenue | zł146.11m |
| Cost of Revenue | zł36.09m |
| Gross Profit | zł110.02m |
| Other Expenses | zł67.68m |
| Earnings | zł42.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 12, 2024
| Earnings per share (EPS) | 2.62 |
| Gross Margin | 75.30% |
| Net Profit Margin | 28.98% |
| Debt/Equity Ratio | 14.7% |
How did MAB perform over the long term?
See historical performance and comparison